Laura Bukavina, Assistant Professor of Urologic Oncology at Case Western Reserve University, shared Alan Tan’s, Associate Professor of Medicine at Vanderbilt University Medical Center, VP of MRD Research and Clinical Strategy at Tempus AI, post on X, adding:
“Couldn’t agree more.
Targeting biology rather than escalating EVP doses is the next frontier but systemic toxicity vs surgical consolidation is debatable and patient onc and QOL outcomes are what counts.
A Curative cystectomy is still a win.”
Quoting Alan Tan’s post:
“Yes it would be a logistical nightmare to do a mega study like this, Alliance for Clinical Trials in Oncology, Stephanie Berg, Andrea Apolo, maybe this is a future roadmap for how we get there one question at a time.
Targeting biology will likely be more important than increasing the cumulative doses of EV. Is there loss of NECTIN-4, would a switch from MMAE to TOPO-1 finish the job?
Bishoy M. Faltas also shared amazing work from his lab on resistance mechanisms.”
Other articles featuring Laura Bukavina and Alan Tan on OncoDaily.
